Product Description
Transdermal contraceptive delivery system (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02158572)
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Agile
Company Location: PRINCETON NJ 08540-1715
Company CEO: Alfred Altomari
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Contraception|Pregnancy Outcomes
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TCDS | P3 |
Completed |
Pregnancy Outcomes |
2016-11-01 |
|
| 2011-000087-95 | P3 |
Active, not recruiting |
Contraception |
2012-11-03 |
|
| ATI-CL12 | P3 |
Completed |
Contraception |
2011-12-01 |
|
| ATI-CL13 | P3 |
Completed |
Contraception |
2011-06-01 |